LUMOS PHARMA INC. - C

Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints

07 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting

26 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

14 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Lumos Pharma Announces Participation in Investor Conferences in September

07 Sep 2023 15:34:06 By Nasdaq GlobeNewswire

Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape

22 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update

09 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023

26 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit

12 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Lumos Pharma Announces Departure of Chief Medical Officer

28 Jun 2023 15:01:00 By Nasdaq GlobeNewswire

Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

21 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference

31 May 2023 07:00:00 By Nasdaq GlobeNewswire

Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st

25 May 2023 07:00:01 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in World Orphan Drug Congress USA

22 May 2023 08:00:01 By Nasdaq GlobeNewswire

Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)

08 May 2023 07:00:01 By Nasdaq GlobeNewswire

Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates

03 May 2023 15:05:01 By Nasdaq GlobeNewswire

Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)

27 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

19 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023

09 Mar 2023 15:05:01 By Nasdaq GlobeNewswire

Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology

05 Mar 2023 13:00:00 By Nasdaq GlobeNewswire

Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates

01 Mar 2023 15:05:01 By Nasdaq GlobeNewswire